3M Drug Delivery Systems has entered into an exclusive licensing agreement with Spirig Pharma, under which Spirig Pharma will utilize one of 3M's immune response modifier (IRM) molecules to further its development of treatment for sun damaged skin.
In addition, 3M has IRMs available for license in the areas of cancer, asthma/allergy and as vaccine adjuvants.
3M Drug Delivery Systems Vaccine Business Development director Mark Tomai said the molecule offers potential for treating patients that suffer from a variety of dermatologic conditions.
Spirig Pharma CEO Silvio Inderbitzin said they are excited to expand their franchise of dermatology offerings in the prevention and treatment of sun damage-related skin conditions.
"With 3M’s IRM molecule, we can enhance our portfolio with the help of an experienced partner in drug delivery technologies," Inderbitzin said.